drugset
drugset / Trial / NCT04240223

A Study to Investigate the Use of Delayed Release Tablets for Colonic Delivery of Brilacidin in Healthy Volunteers

NCT04240223 ↗

Phase 1 Completed 9 enrolled Innovation Pharmaceuticals, Inc.
RandomizedSequentialSingle-blindOther

Summary

This is a single-centre, blinded, randomized, placebo controlled, dose escalation study. Up to 9 healthy male volunteers will participate in the study. This study is designed to investigate the use of delayed release tablets for colonic delivery of Brilacidin.

Timeline

Start
2020-01-06
Primary completion
2020-02-12
Completion
2020-02-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Brilacidin Other / unclassified 50 mg Oral
Subject Brilacidin Other / unclassified 100 mg Oral
Subject Brilacidin Other / unclassified 200 mg Oral

Indications

No indication recorded.